Biogen’s Lowest Diranersen Dose Outperforms Higher Doses in CELIA
The double-blind CELIA study evaluated diranersen in 416 people with Alzheimer’s disease. Biogen tested 60 mg every six months, 115 mg every six months, and 115 mg every three months.
However, the 60 mg group produced the strongest result. Compared with placebo, this regimen slowed decline by 0.54 points, or 26%, on the Clinical Dementia Rating–Sum of Boxes. It also slowed decline by 42% on ADAS-Cog13 and 50% on MMSE. Most differences reached nominal statistical significance.
CELIA’s Failed Dose Response Puts Biogen’s Phase III Plan Under Pressure
CELIA did not simply test whether diranersen could outperform placebo. Instead, Biogen designed it to determine whether higher doses produced greater benefit on CDR-SB after 18 months.
Yet the results moved in the opposite direction. The 115 mg dose every six months slowed CDR-SB decline by 14%, while the same dose every three months achieved a 9% reduction. Therefore, CELIA failed its primary endpoint because higher exposure did not create stronger benefit.
Tau Levels Fall Sharply, but Biogen Finds No Clear Clinical Dose Response
Meanwhile, diranersen showed strong biological activity. Across all dose groups, the drug reduced cerebrospinal fluid total tau by 50% to 65% from baseline. Moreover, the tau PET substudy found reductions across all brain regions.
These findings support target engagement. Nevertheless, the biomarker response did not explain why the lowest dose produced the strongest clinical signal. This disconnect now complicates dose selection and interpretation of the Phase II evidence.
Positive Secondary Endpoints Cannot Erase CELIA’s Primary Endpoint Failure
Biogen reported benefits across several secondary cognitive endpoints, especially in the 60 mg group. Still, nominal significance does not replace a successful primary endpoint or confirm that the effect will repeat in a larger study.
The company must separate a true treatment effect from variability across dose groups. In addition, the lack of separation from placebo on ADCS-ADL-MCI leaves uncertainty around daily functioning, although longer follow-up continues.
Biogen Must Solve Its Diranersen Dose Puzzle Before Phase III Begins
Biogen plans to advance diranersen into confirmatory Phase III development and consult health authorities. Consequently, the next protocol must justify the selected dose, define a defensible endpoint strategy, and test whether the 60 mg result remains consistent in a larger population.
Zamann Pharma’s Quality Management System service helps pharmaceutical teams build practical risk controls, structured reviews, and compliant decision processes. Explore the service to strengthen quality governance before critical development decisions move into execution.
Source: Clinicaltrialsarena.Com